(Q44109055)

29 November 2017

Eculizumab for paroxysmal nocturnal haemoglobinuria (English)

1 reference

29 November 2017

Charles Parker

1

1 reference

PubMed ID

19144399

29 November 2017

language of work or name

English

0 references

publication date

12 January 2009

1 reference

29 November 2017

1 reference

29 November 2017

373

1 reference

29 November 2017

9665

1 reference

29 November 2017

759-767

1 reference

Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

1 reference

7 January 2021

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

The central role of the alternative complement pathway in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

The pathophysiology of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Diagnosis and management of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Drugs for exceptionally rare diseases: do they deserve special status for funding?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Complement-specific antibodies: Designing novel anti-inflammatories

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Natural history of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Orphan drugs and the NHS: should we value rarity?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Paroxysmal nocturnal haemoglobinuria with coexisting deficiency of the ninth component of complement: lack of massive haemolytic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Complement in lupus nephritis: the good, the bad, and the unknown

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

Latest treatment strategies for membranous nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960001-5

7 January 2021

10.1016/S0140-6736(09)60001-5

Identifiers

DOI

1 reference

29 November 2017

1 reference

PubMed ID

19144399